Helus Pharma at TD Cowen summit: late-stage psychedelic bet takes shape

Helus Pharma, formerly known as Cybin Inc., presented its late-stage strategy at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026, focusing on deuterated serotonergic drugs for mental health disorders. The company highlighted its lead program, HLP-003, a deuterated psilocin drug, which is on track for Phase III data from the APPROACH trial in Q4 2024.

Management emphasized the potential benefits of deuteration, including improved stability, faster brain penetration, and reduced drug-drug interaction risks compared to parent psilocybin. HLP-003 is targeting adjunctive major depressive disorder, a market currently dominated by adjunctive antipsychotics. The company also announced HLP-004 for generalized anxiety disorder and HLP-005 as an early-stage library program.

No financial results were discussed during the summit, with management focusing solely on clinical development, regulatory timing, and the company's scientific strategy.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.